Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KAINOS LaboratoriesTSE:4556 40 EPS without NRI is 円129.43 as of Mar. 2026. GuruFocus rates TSE:4556 with a GF Score™ of 40/100 and a GF Value™ of 円1,283.10 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 661 Medical Devices & Instruments companies, KAINOS Laboratories ranks worse than 63.69% on this metric.
KAINOS Laboratories's earnings per share without non-recurring items for the
six
months ended in Mar. 2026 was 円56.73.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 円129.43.
During the past 12 months, KAINOS Laboratories's average earnings per share (NRI) Growth Rate was -13.30% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -1.40% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 4.80% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 7.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for KAINOS Laboratories's EPS without NRI or its related term are showing as below:
TSE:4556'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -1.4 Med: 10.6 Max: 722.2
Current: -1.4
During the past 13 years, KAINOS Laboratories's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 722.20% per year. The lowest was -1.40% per year. And the median was 10.60% per year.
TSE:4556's 3-Year EPS without NRI Growth Rate is ranked worse than 63.69% of 661
companies
in the Medical Devices & Instruments industry
Industry Median: 8.2
vs TSE:4556: -1.40
KAINOS Laboratories's EPS (Basic) for the
six
months ended in Mar. 2026 was 円33.54.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was 円106.19.
KAINOS Laboratories (TSE:4556) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
KAINOS Laboratories EPS without NRI Related Terms
KAINOS Laboratories EPS without NRI Historical Data
* Premium members only.
The historical data trend for KAINOS Laboratories's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4556 vs ISRG, BDX, MDLN: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KAINOS Laboratories PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where KAINOS Laboratories's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円129.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAINOS Laboratories (TSE:4556) has a EPS without NRI of 円129.43 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on KAINOS Laboratories and its competitors. According to the industry distribution chart, KAINOS Laboratories ranks #421 out of 661 companies in the Medical Devices & Instruments industry, placing it in the top 63.7%.
Is KAINOS Laboratories' EPS without NRI too high?
KAINOS Laboratories' current EPS without NRI is 円129.43. Based on the distribution chart, KAINOS Laboratories ranks #421 out of 661 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, KAINOS Laboratories has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KAINOS Laboratories ranks #421 out of 661 companies for EPS without NRI. This places KAINOS Laboratories in the lower half of its industry. The industry median EPS without NRI is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.20, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current EPS without NRI is 円129.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,283.10, compared to a current price of 円2,268.00 — trading 76.8% above its estimated fair value. The current EPS without NRI is 円129.43. KAINOS Laboratories' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current EPS without NRI is 円129.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?
Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued.
The current stock price of 円2,268.00 is trading 76.8% above its estimated GF Value™ of 円1,283.10.
GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.
Key valuation signals for TSE:4556:
EPS without NRI: 円129.43
GF Value™: 円1,283.10 vs. price of 円2,268.00 (76.8% above fair value)
No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
40GF Score
Get the complete analysis for TSE:4556
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4556 has been successfully added to your 
